Cell and Gene Outsourcing

  1. Solving Challenges For Vectors That Are Complex In Practice 7/8/2026

    Overcome adenoviral scale-up challenges with a design-to-scale manufacturing framework that optimizes cell growth, boosts vector productivity, and supports reliable clinical supply.

  2. Maximizing Efficiency In Lentiviral Vector Manufacturing 7/8/2026

    Accelerate cell and gene therapy programs with scalable lentiviral vector manufacturing, delivering high titers, exceptional purity, and reliable clinical supply from gene to clinic.

  3. Optimizing Adenoviral Production With Adaptive Process Architecture 7/8/2026

    Speed adenoviral vector development with scalable suspension processes and hybrid purification workflows that improve yield, efficiency, and clinical readiness.

  4. Advancing AAV Therapies From Concept To Commercial Supply 7/8/2026

    Accelerate gene therapy development with a scalable AAV platform delivering high yield, reproducibility, integrated analytics, and reliable clinical supply from design to production.

  5. Viral Vector Solutions That Move Your Program Forward 7/8/2026

    Optimize your viral vector program with scalable manufacturing, advanced process development, regulatory-ready workflows, and integrated fill-finish solutions to accelerate market success.

  6. Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis 7/8/2026

    Since every sponsor–CDMO relationship can have widely different scopes, requirements, and procedures, this article focuses on the basic principles for analyzing and managing the risks of not achieving the relationship’s objectives.

  7. CAR-T Has A Geography Problem 7/6/2026

    Cellular immunotherapies deliver strong clinical results, but centralized manufacturing and complex logistics limit access. Regional, standardized production can expand global patient access.

  8. How To Prevail Over Common Bottlenecks In Recombinant Protein Development 7/1/2026

    Early CMC and expression system decisions in recombinant protein development shape quality, cost, and manufacturability, while cross-functional collaboration helps avoid bottlenecks when scaling to commercial production.

  9. Accelerating Biologics Release Testing Without Increasing Risk 7/1/2026

    Streamline biologics release testing by balancing automated speed with regulatory compliance. High-throughput, validated workflows reduce timelines and error risks for safe, rapid, audit-ready delivery.

  10. Evaluation Of Synthetic DNA As An Alternative To Plasmid DNA 6/30/2026

    Synthetic DNA replaces plasmids for AAV production, cutting contaminants and variability and improving reproducibility and scalability from research to manufacturing.